Impact of biomarker changes during neoadjuvant chemotherapy for clinical response in patients with residual breast cancers

International Journal of Clinical Oncology
Yukie EnomotoYasuo Miyoshi

Abstract

Residual cancer burden or Ki67 expression levels in residual tumors reportedly provided significant prognostic information for a non-pathological complete response subset after neoadjuvant chemotherapy (NAC). However, the significance of Ki67 reduction for clinical response during chemotherapy in each subtype or menopausal status is yet to be determined. A total of 183 breast cancers surgically removed after chemotherapy were recruited for this study. Expression levels of estrogen receptor (ER), progesterone receptor (PgR), and Ki67 were determined immunohistochemically for semiquantitative measurement and these biomarkers were compared in pre- and post-NAC samples from pathological non-responders (n = 125). Responses to chemotherapy were evaluated both clinically and pathologically. Ki67 expression levels after NAC (median 5 %, range 0-70 %) were significantly reduced compared with before NAC (25, 1-80 %, P < 0.0001), but only in patients who attained clinical response. This significant suppression of Ki67 in clinical responders was consistently observed in breast cancers from the ER-positive subset, but not the ER-negative subset in the total test set (n = 120). These observations were also made in the validation set (n = 63)...Continue Reading

References

Aug 26, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·O PaganiH J Senn
Nov 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roman RouzierGabriel N Hortobagyi
Mar 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Valentina GuarneriAna M Gonzalez-Angulo
Feb 13, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C MazouniL Pusztai
Sep 6, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W Fraser SymmansLajos Pusztai
Jan 9, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marta GuixCarlos L Arteaga
Jul 2, 2008·Breast Cancer Research and Treatment·Robin L JonesMitchell Dowsett
Jun 13, 2009·Breast Cancer Research : BCR·Joan S Lewis-Wambi, V Craig Jordan
Jun 4, 2010·The New England Journal of Medicine·Sandra M SwainNorman Wolmark
Nov 30, 2010·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·T TaneiS Noguchi
Oct 30, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A RomeroT Caldés
Jul 3, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gunter von MinckwitzCarsten Denkert
Sep 5, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gunter von MinckwitzSibylle Loibl

❮ Previous
Next ❯

Citations

Feb 23, 2018·European Journal of Nutrition·Nuri El-AzemMCarmen Ramirez-Tortosa
Jul 2, 2020·OncoTargets and Therapy·Weilin XuJinhai Tang
Jul 20, 2020·BMC Cancer·Laura Rey-VargasSilvia J Serrano-Gomez
Mar 23, 2021·Annals of Surgical Oncology·Srivarshini Cherukupalli MohanAlice P Chung

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Ductal

Ductal carcinoma is a malignant neoplasm involving the ductal systems of any of a number of organs, such as the mammary glands, pancreas, prostate or lacrimal gland. Discover the latest research on ductal carcinoma here.

Carcinoma, Lobular

Lobular carcinoma is an invasive type of breast cancer in which lobules, areas of the breast that produce milk, undergo malignant transformation. Here is the latest research.